A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
A Single-Center Retrospective Study About Efficacy and Safety of Eribulin-Based Regimen in the Treatment of Metastatic Triple-Negative Breast Cancer and Comparison With Other Chemotherapy Regimen
Epistemonikos ID: df138ef5e15b95d0e5234d34d61cb4b43c943f47
First added on: May 15, 2024